KarXT
Phase 3Recruiting 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Bipolar Disorder Type I With Mania or Mania With Mixed Features
Conditions
Bipolar Disorder Type I With Mania or Mania With Mixed Features
Trial Timeline
Jun 13, 2025 → Nov 2, 2026
NCT ID
NCT06951711About KarXT
KarXT is a phase 3 stage product being developed by Bristol Myers Squibb for Bipolar Disorder Type I With Mania or Mania With Mixed Features. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06951711. Target conditions include Bipolar Disorder Type I With Mania or Mania With Mixed Features.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07288567 | Phase 3 | Recruiting |
| NCT07061288 | Phase 1 | Recruiting |
| NCT06951711 | Phase 3 | Recruiting |
| NCT06951698 | Phase 3 | Recruiting |
| NCT06882785 | Phase 3 | Recruiting |
Competing Products
20 competing products in Bipolar Disorder Type I With Mania or Mania With Mixed Features
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Olanzapine | Eli Lilly | Phase 3 | 77 |
| Valproate + Lithium + Risperidone + Olanzapine | Eli Lilly | Phase 3 | 77 |
| Olanzapine + Placebo | Eli Lilly | Approved | 85 |
| FK949E | Astellas Pharma | Phase 3 | 77 |
| FK949E | Astellas Pharma | Phase 3 | 77 |
| FK949E + Placebo | Astellas Pharma | Phase 2/3 | 65 |
| Escitalopram + Bupropion XL | Lupin Limited | Phase 3 | 77 |
| Olanzapine | Eli Lilly | Approved | 85 |
| Olanzapine Hydrochloride + Lithium Carbonate | Eli Lilly | Phase 3 | 77 |
| olanzapine + lithium + valproate + carbamazepine | Eli Lilly | Phase 3 | 77 |
| Olanzapine | Eli Lilly | Approved | 85 |
| Olanzapine | Eli Lilly | Phase 3 | 77 |
| LY2979165 + Placebo | Eli Lilly | Phase 1 | 33 |
| olanzapine + divalproex sodium + placebo | Eli Lilly | Approved | 85 |
| olanzapine + risperidone | Eli Lilly | Approved | 85 |
| LY2979165 + placebo | Eli Lilly | Phase 1 | 33 |
| Topiramate + Placebo | Eli Lilly | Approved | 85 |
| olanzapine | Eli Lilly | Phase 3 | 77 |
| Olanzapine + Placebo | Eli Lilly | Phase 3 | 77 |
| Brenipatide + Placebo | Eli Lilly | Phase 2 | 52 |